Functions of cytokine induced killer cells in oncotherapy

doi:10.3760/cma.j.issn.1673-422X.2013.12.009

Abstract

Abstract: Cytokine induced killer (CIK) cells are the main immune cells for tumor immnuotherapy. Relevant basic researches show that CIK cells have significant antitumor effects for various hematologic tumor and solid tumors. Clinical studies confirm that CIK cellsbased therapy have exact therapeutic effect and mild adverse reaction for tumor patients. So CIK cellsbased therapy is a promising and safe method and it is important to establish standards for cultivating and using CIK cells.

Key words: Killer cells, Immunotherapy, Dendritic cells

GAO Meng, YUN Sheng. Functions of cytokine induced killer cells in oncotherapy[J]. Journal of International Oncology, 2013, 40(12): 908-911.

References

［1］ Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokineinduced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther, 2012, 12(6): 673684. ［2］ Pievani A, Borleri G, Pende D, et al. Dualfunctional capability of CD3+CD56+ CIK cells, a Tcell subset that acquires NK function and retains TCRmediated specific cytotoxicity. Blood, 2011, 118(12): 33013310. ［3］ Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cellviral biotherapy. Science, 2006, 311(5768): 17801784. ［4］ Franceschetti M, Pievani A, Borleri G, et al. Cytokineinduced killer cells are terminally differentiated activated CD8 cytotoxic TEMRA lymphocytes. Exp Hematol, 2009, 37(5): 616628. ［5］ Joshi PS, Liu JQ, Wang Y, et al. Cytokineinduced killer T cells kill immature dendritic cells by TCRindependent and perforindependent mechanisms. J Leukoc Biol, 2006, 80(6): 13451353. ［6］ Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokineinduced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res, 2011, 35(9): 11361142. ［7］司玉玲, 庞华, 綦振家, 等. 耐药乳腺癌免疫治疗的实验研究. 天津医药, 2012, 40(4): 359362. ［8］李应林, 李宁, 李冉, 等. CIK对人肺腺癌耐顺铂细胞A549/DDP杀伤效应及耐药逆转作用. 遵义医学院学报, 2012, 35(5): 404406. ［9］ Wang YF, Kunda PE, Lin JW, et al. Cytokineinduced killer cells cocultured with complete tumor antigenloaded dendritic cells, have enhanced selective cytotoxicity on carboplatinresistant retinoblastoma cells. Oncol Rep, 2013, 29(5): 18411850. ［10］梅家转, 刘桂举, 张晓娟, 等. IL12增强CIK细胞对食管癌EC9706细胞的杀伤活性. 中国肿瘤生物治疗杂志, 2013, 20(2): 197200. ［11］ Rettinger E, Kuci S, Naumann I, et al. The cytotoxic potential of interleukin15stimulated cytokineinduced killer cells against leukemia cells. Cytotherapy, 2012, 14(1): 91103. ［12］ Pievani A, Belussi C, Klein C, et al. Enhanced killing of human Bcell lymphoma targets by combined use of cytokineinduced killer cell (CIK) cultures and antiCD20 antibodies. Blood, 2011, 117(2): 510518．［13］ Bonanno G, Iudicone P, Mariotti A, et al. Thymoglobulin, intederon7 and interleukin2 efficiently expand cytokineinduced killer (CIK) cells in clinicalgrade cultures. J Transl Med, 2010, (8): 129. ［14］ Nagaraj S, Ziske C, SchmidtWolf IG. Human cytokineinduced killer cells have enhanced in vitro cytolytic activity via nonviral interleukin2 gene transfer. Genet Vaccines Ther, 2004, 2(1): 12. ［15］ Kornacker M, Verneris M, Kornacker B, et al. The apoptotic and proliferative fate of cytokineinduced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy, 2006, 8(1): 1323. ［16］ Matin V, Pizzitola I, Agostoni V, et al. Cytokineinduced killer cells for cell therapy of acute myeloid leukemial improvement of their immune activity by expression of CD33specific chimeric receptors. Haematologica, 2010, 95(12): 21442152. ［17］ Huang X, Chen YT, Song HZ, et al. Cisplatin pretreatment enhances antitumor activity of cytokineinduced killer cells. World J Gastroenterol, 2011, 17(25): 30023011. ［18］ Yang Z, Zhang Q, Xu K, et al. Combined therapy with cytokineinduced killer cells and oncolytic adenovirus expressing IL12 induce enhanced antitumor activity in liver tumor model. PLoS One, 2012, 7(9): e44802. ［19］ Ma Y, Zhang Z, Tang L, et al. Cytokineinduced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy, 2012, 14(4): 483493. ［20］董毅, 朱太岗, 李月红, 等. CIK细胞与DCCIK 细胞抗肿瘤效应的对照研究. 中华全科医学, 2011, 9(12): 18441938. ［21］ Li X, Xu B, Wu J, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol, 2012, 14 (5): 102108. ［22］ Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells:first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 2011, 137(2): 305310. ［23］ Ren J, Di L, Song G, et al. Selections of appropriate regimen of highdose chemotherapy combined with adoptive cellular therapy with dendritic and cytokineinduced killer cells improved progressionfree and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol, 2013, 15（10）： 780788. ［24］张澎, 张静, 刘亮, 等. CIK 治疗转移性肾癌的临床疗效评价及预后影响因素分析. 中国肿瘤临床, 2012, 39(10): 732735. ［25］ Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DCactivated CIKs to chemotherapy treatment in a single cohort of advanced nonsmallcell lung cancer patients. Cancer Immunology, Immunotherapy, 2013, 62, (1): 6573. ［26］彭大为, 李建旺, 元建华, 等. 自体DCCIK细胞联合培美曲塞治疗老年非小细胞肺癌的疗效与安全性. 中国免疫学杂志, 2012, 28(7): 648656. ［27］宋东, 杨晓玲, 冯慧晶, 等. DCCIK 联合化疗治疗消化道肿瘤临床疗效分析. 中国肿瘤临床, 2012, 39(9): 497501. ［28］王赛男, 高海燕, 潘欣, 等. DCCIK治疗对肾癌患者淋巴细胞亚群的影响. 中国肿瘤生物治疗杂志, 2012, 19(3): 309312. ［29］赵明明, 洪珞珈, 孙国勋, 等. DCCIK细胞联合治疗158例恶性肿瘤的免疫疗效观察. 哈尔滨医科大学学报, 2013, 47(1): 6066. ［30］ Zhao Q, Zhang H, Li Y, et al. Antitumor effects of CIK combined with oxaliplatin in human oxaliplatinresistant gastric cancer cells in vivo and in vitro. J Exp Cancer Res, 2010, 29: 118. ［31］ Qiu Y, Xu MB, Yun MM, et al. Hepatocellular carcinomaspecific immunotherapy with synthesized α1,3galactosyl epitopepulsed dendritic cells and cytokineinduced killer cells. World J Gastroenterol, 2011, 17(48): 52605266. ［32］ Qiu Y, Yun MM, Xu MB, et al. Pancreatic carcinomaspecific immunotherapy using synthesised alphagalactosyl epitopeactivated immuneresponders: findings from a pilot study. Int J Clin Oncol, 2013, 18(4): 657665. ［33］龚奕, 陈幸华, 张曦, 等. DCCIK细胞输注治疗急性髓细胞白血病50例分析. 重庆医学, 2011, 40(30): 30393041. ［34］杨皎娃, 邓琦, 李玉明. DCCIK共培养在AL化疗后免疫治疗中的应用及其对NKG2D表达的影响. 山东医药, 2013, 53(2): 13. ［35］ Chang C, Yang B, Zhang L, et al. Curative effect of decitabine combined with cytokineinduced killer cells in two elderly patients with acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2013, 21(1): 6267. ［36］ Tang H, Sampath P, Yan X, et al. Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination. Gene Ther, 2013, 20(7): 770778.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[14]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[15]	Ma Pengcheng, Chen Yu. Research progress of primary pulmonary lymphoepithelioma-like carcinoma [J]. Journal of International Oncology, 2023, 50(3): 174-178.